Oruka Therapeutics, Inc. (ORKA) 10-Year Financial Performance & Capital Metrics

ORKA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Show more

Revenue $0
EBITDA -$88M -805.7%
Net Income -$84M -743.5%
EPS (Diluted) -4.99 +39.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.5% -84.5%
ROIC -41.15%
Debt/Equity 0.00 -72.4%
Interest Coverage -60.03

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓Trading near 52-week high
✓Trading at only 1.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 16.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-94.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.35%

ROCE

10Y Avg-59.98%

5Y Avg-44.58%

3Y Avg-33.96%

Latest-41.48%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-12K	-19K	-24K	-27K	-22K	-89K	-93K	-91K	-114K	-27K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.54%	-0.58%	-0.26%	-0.13%	0.19%	-3.05%	-0.04%	0.02%	-0.25%	0.76%
Operating Expenses+	9.68M	11.44M	16.59M	18.68M	8.1M	5.72M	9.67M	19.24M	9.73M	88.1M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	4.06M	4.37M	4.24M	4.61M	3.86M	3.89M	4.68M	5.41M	5.26M	13.04M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.63M	7.06M	12.35M	14.08M	4.24M	1.83M	4.99M	13.83M	4.46M	75.06M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-9.69M	-11.46M	-16.61M	-18.71M	-8.12M	-5.81M	-9.77M	-19.34M	-9.84M	-88.12M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.4%	-0.18%	-0.45%	-0.13%	0.57%	0.28%	-0.68%	-0.98%	0.49%	-7.95%
EBITDA+	-9.68M	-11.44M	-16.59M	-18.68M	-8.1M	-5.72M	-9.67M	-19.24M	-9.73M	-88.1M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.4%	-0.18%	-0.45%	-0.13%	0.57%	0.29%	-0.69%	-0.99%	0.49%	-8.06%
D&A (Non-Cash Add-back)	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
EBIT	-9.69M	-11.45M	-16.44M	-18.55M	-7.96M	-5.64M	-9.74M	-19.32M	-9.93M	-82.26M
Net Interest Income+	7K	14K	169K	0	0	-7K	-9K	0	675K	4.39M
Interest Income	7K	14K	169K	0	0	0	0	0	675K	5.86M
Interest Expense	0	0	0	0	0	7K	9K	0	0	1.47M
Other Income/Expense	4K	10K	169K	161K	154K	165K	19K	13K	-85K	4.4M
Pretax Income+	-9.69M	-11.45M	-16.44M	-18.55M	-7.96M	-5.65M	-9.75M	-19.32M	-9.93M	-83.72M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-61K	-31K	-167K	-9K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	0.97%	1%	1%	1%	1%
Net Income+	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.4%	-0.18%	-0.44%	-0.12%	0.57%	0.31%	-0.78%	-0.98%	0.49%	-7.43%
Net Income (Continuing)	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-710.64	-393.12	-390.96	-382.87	-123.73	-49.79	-8.40	-16.68	-8.27	-4.99
EPS Growth %	0.55%	0.45%	0.01%	0.02%	0.68%	0.6%	0.83%	-0.99%	0.5%	0.4%
EPS (Basic)	-710.64	-393.12	-390.96	-382.87	-123.73	-49.79	-8.40	-16.68	-8.27	-4.99
Diluted Shares Outstanding	13.56K	29.12K	41.98K	48.29K	64.11K	110.1K	4.71M	13.9M	14.41M	16.79M
Basic Shares Outstanding	13.56K	29.12K	41.98K	48.29K	64.11K	110.1K	4.71M	13.9M	14.41M	16.79M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Total Current Assets+	15.49M	38.92M	21.45M	12.3M	6.78M	8.48M	49.97M	54.42M	42.7M	376.87M
Cash & Short-Term Investments	15.35M	38.8M	21.16M	11.75M	6.61M	8.36M	49.07M	53.36M	42.45M	375.65M
Cash Only	15.35M	38.8M	7.4M	8.7M	6.61M	8.36M	49.07M	53.36M	42.45M	61.58M
Short-Term Investments	0	0	13.76M	3.05M	0	0	0	0	0	314.07M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	134K	114K	282K	547K	169K	117K	897K	1.06M	254K	1.22M
Total Non-Current Assets+	644K	658K	3.18M	66K	48K	56K	461K	503K	386K	19.15M
Property, Plant & Equipment	36K	28K	66K	42K	24K	32K	449K	485K	368K	1.04M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	2.35M	0	0	0	0	0	0	18.07M
Other Non-Current Assets	608K	630K	766K	24K	24K	24K	12K	18K	18K	43K
Total Assets+	16.13M	39.57M	24.63M	12.37M	6.83M	8.54M	50.43M	54.92M	43.09M	396.02M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.06%	1.45%	-0.38%	-0.5%	-0.45%	0.25%	4.91%	0.09%	-0.22%	8.19%
Total Current Liabilities+	1.39M	1.5M	2.4M	2.07M	793K	926K	3.5M	3.5M	1.13M	13.04M
Accounts Payable	0	0	0	622K	230K	418K	1.77M	1.12M	334K	3.46M
Days Payables Outstanding	-	-	-	8.41K	3.82K	1.71K	6.96K	4.48K	1.07K	46.8K
Short-Term Debt	0	0	0	0	0	25K	41K	100K	103K	213K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.06M	835K	1.68M	691K	413K	354K	870K	1.36M	522K	7.33M
Current Ratio	11.16x	25.88x	8.95x	5.94x	8.55x	9.16x	14.28x	15.56x	37.72x	28.89x
Quick Ratio	11.16x	25.88x	8.95x	5.94x	8.55x	9.16x	14.28x	15.56x	37.72x	28.89x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3K	0	39K	20K	0	0	409K	383K	280K	755K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	409K	383K	280K	755K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	39K	20K	0	0	0	0	0	0
Total Liabilities	1.39M	1.5M	2.44M	2.09M	793K	926K	3.91M	3.88M	1.41M	13.8M
Total Debt+	0	0	0	0	0	25K	450K	483K	383K	968K
Net Debt	-15.35M	-38.8M	-7.4M	-8.7M	-6.61M	-8.34M	-48.62M	-52.88M	-42.06M	-60.61M
Debt / Equity	-	-	-	-	-	0.00x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-830.57x	-1085.11x	-	-	-60.03x
Total Equity+	14.74M	38.07M	22.19M	10.28M	6.03M	7.61M	46.52M	51.04M	41.67M	382.22M
Equity Growth %	-0.05%	1.58%	-0.42%	-0.54%	-0.41%	0.26%	5.11%	0.1%	-0.18%	8.17%
Book Value per Share	1087.17	1307.48	528.71	212.76	94.08	69.12	9.88	3.67	2.89	22.77
Total Shareholders' Equity	14.74M	38.07M	22.19M	10.28M	6.03M	7.61M	46.52M	51.04M	41.67M	382.22M
Common Stock	21K	9K	9K	12K	14K	2K	10K	14K	14K	37K
Retained Earnings	-84.62M	-96.07M	-112.51M	-131M	-138.93M	-144.42M	-154.15M	-173.48M	-183.4M	-83.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-19K	-2K	0	0	0	0	0	-41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Cash from Operations+	-9.41M	-10.53M	-14.99M	-17.47M	-8.24M	-4.8M	-7.72M	-18.76M	-10.91M	-57.84M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.78%	-0.12%	-0.42%	-0.17%	0.53%	0.42%	-0.61%	-1.43%	0.42%	-4.3%
Net Income	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Depreciation & Amortization	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	714K	788K	1.03M	906K	275K	151K	43K	497K	561K	14.27M
Working Capital Changes	-443K	104K	400K	85K	-608K	441K	1.88M	-28K	-1.66M	11.59M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	-583K	-392K	188K	1.1M	-411K	-783K	3.46M
Cash from Investing+	-19K	-11K	-16.41M	12.93M	3.05M	-4K	-19K	-43K	-2K	-330.13M
Capital Expenditures	-19K	-11K	-12K	-3K	-4K	-4K	-19K	-43K	-2K	-189K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	8.02M	33.99M	0	5.85M	3.1M	6.56M	48.45M	23.09M	0	449.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-179K	-193K	0	-256K	-311K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.43M	-10.54M	-15M	-17.48M	-8.25M	-4.8M	-7.74M	-18.8M	-10.91M	-58.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.77%	-0.12%	-0.42%	-0.17%	0.53%	0.42%	-0.61%	-1.43%	0.42%	-4.32%
FCF per Share	-695.11	-362.16	-357.31	-361.85	-128.64	-43.64	-1.64	-1.35	-0.76	-3.46
FCF Conversion (FCF/Net Income)	0.97x	0.92x	0.91x	0.94x	1.04x	0.88x	0.79x	0.97x	1.10x	0.69x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
Return on Equity (ROE)	-63.91%	-43.34%	-54.57%	-113.89%	-97.3%	-80.37%	-35.98%	-39.61%	-21.41%	-39.5%
Return on Invested Capital (ROIC)	-	-	-177.22%	-171.5%	-1221.36%	-	-	-	-	-41.15%
Debt / Equity	-	-	-	-	-	0.00x	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-	-	-	-	-	-830.57x	-1085.11x	-	-	-60.03x
FCF Conversion	0.97x	0.92x	0.91x	0.94x	1.04x	0.88x	0.79x	0.97x	1.10x	0.69x

Frequently Asked Questions

Growth & Financials

Oruka Therapeutics, Inc. (ORKA) grew revenue by 0.0% over the past year. Growth has been modest.

Oruka Therapeutics, Inc. (ORKA) reported a net loss of $109.2M for fiscal year 2024.

Dividend & Returns

Oruka Therapeutics, Inc. (ORKA) has a return on equity (ROE) of -39.5%. Negative ROE indicates the company is unprofitable.

Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $84.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Oruka Therapeutics, Inc. (ORKA) 10-Year Financial Performance & Capital Metrics

ORKA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$88M -805.7%
Net Income -$84M -743.5%
EPS (Diluted) -4.99 +39.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.5% -84.5%
ROIC -41.15%
Debt/Equity 0.00 -72.4%
Interest Coverage -60.03

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓Trading near 52-week high
✓Trading at only 1.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 16.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-94.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.35%

ROCE

10Y Avg-59.98%

5Y Avg-44.58%

3Y Avg-33.96%

Latest-41.48%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-12K	-19K	-24K	-27K	-22K	-89K	-93K	-91K	-114K	-27K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.54%	-0.58%	-0.26%	-0.13%	0.19%	-3.05%	-0.04%	0.02%	-0.25%	0.76%
Operating Expenses+	9.68M	11.44M	16.59M	18.68M	8.1M	5.72M	9.67M	19.24M	9.73M	88.1M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	4.06M	4.37M	4.24M	4.61M	3.86M	3.89M	4.68M	5.41M	5.26M	13.04M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.63M	7.06M	12.35M	14.08M	4.24M	1.83M	4.99M	13.83M	4.46M	75.06M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-9.69M	-11.46M	-16.61M	-18.71M	-8.12M	-5.81M	-9.77M	-19.34M	-9.84M	-88.12M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.4%	-0.18%	-0.45%	-0.13%	0.57%	0.28%	-0.68%	-0.98%	0.49%	-7.95%
EBITDA+	-9.68M	-11.44M	-16.59M	-18.68M	-8.1M	-5.72M	-9.67M	-19.24M	-9.73M	-88.1M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.4%	-0.18%	-0.45%	-0.13%	0.57%	0.29%	-0.69%	-0.99%	0.49%	-8.06%
D&A (Non-Cash Add-back)	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
EBIT	-9.69M	-11.45M	-16.44M	-18.55M	-7.96M	-5.64M	-9.74M	-19.32M	-9.93M	-82.26M
Net Interest Income+	7K	14K	169K	0	0	-7K	-9K	0	675K	4.39M
Interest Income	7K	14K	169K	0	0	0	0	0	675K	5.86M
Interest Expense	0	0	0	0	0	7K	9K	0	0	1.47M
Other Income/Expense	4K	10K	169K	161K	154K	165K	19K	13K	-85K	4.4M
Pretax Income+	-9.69M	-11.45M	-16.44M	-18.55M	-7.96M	-5.65M	-9.75M	-19.32M	-9.93M	-83.72M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-61K	-31K	-167K	-9K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	0.97%	1%	1%	1%	1%
Net Income+	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.4%	-0.18%	-0.44%	-0.12%	0.57%	0.31%	-0.78%	-0.98%	0.49%	-7.43%
Net Income (Continuing)	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-710.64	-393.12	-390.96	-382.87	-123.73	-49.79	-8.40	-16.68	-8.27	-4.99
EPS Growth %	0.55%	0.45%	0.01%	0.02%	0.68%	0.6%	0.83%	-0.99%	0.5%	0.4%
EPS (Basic)	-710.64	-393.12	-390.96	-382.87	-123.73	-49.79	-8.40	-16.68	-8.27	-4.99
Diluted Shares Outstanding	13.56K	29.12K	41.98K	48.29K	64.11K	110.1K	4.71M	13.9M	14.41M	16.79M
Basic Shares Outstanding	13.56K	29.12K	41.98K	48.29K	64.11K	110.1K	4.71M	13.9M	14.41M	16.79M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Total Current Assets+	15.49M	38.92M	21.45M	12.3M	6.78M	8.48M	49.97M	54.42M	42.7M	376.87M
Cash & Short-Term Investments	15.35M	38.8M	21.16M	11.75M	6.61M	8.36M	49.07M	53.36M	42.45M	375.65M
Cash Only	15.35M	38.8M	7.4M	8.7M	6.61M	8.36M	49.07M	53.36M	42.45M	61.58M
Short-Term Investments	0	0	13.76M	3.05M	0	0	0	0	0	314.07M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	134K	114K	282K	547K	169K	117K	897K	1.06M	254K	1.22M
Total Non-Current Assets+	644K	658K	3.18M	66K	48K	56K	461K	503K	386K	19.15M
Property, Plant & Equipment	36K	28K	66K	42K	24K	32K	449K	485K	368K	1.04M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	2.35M	0	0	0	0	0	0	18.07M
Other Non-Current Assets	608K	630K	766K	24K	24K	24K	12K	18K	18K	43K
Total Assets+	16.13M	39.57M	24.63M	12.37M	6.83M	8.54M	50.43M	54.92M	43.09M	396.02M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.06%	1.45%	-0.38%	-0.5%	-0.45%	0.25%	4.91%	0.09%	-0.22%	8.19%
Total Current Liabilities+	1.39M	1.5M	2.4M	2.07M	793K	926K	3.5M	3.5M	1.13M	13.04M
Accounts Payable	0	0	0	622K	230K	418K	1.77M	1.12M	334K	3.46M
Days Payables Outstanding	-	-	-	8.41K	3.82K	1.71K	6.96K	4.48K	1.07K	46.8K
Short-Term Debt	0	0	0	0	0	25K	41K	100K	103K	213K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.06M	835K	1.68M	691K	413K	354K	870K	1.36M	522K	7.33M
Current Ratio	11.16x	25.88x	8.95x	5.94x	8.55x	9.16x	14.28x	15.56x	37.72x	28.89x
Quick Ratio	11.16x	25.88x	8.95x	5.94x	8.55x	9.16x	14.28x	15.56x	37.72x	28.89x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3K	0	39K	20K	0	0	409K	383K	280K	755K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	409K	383K	280K	755K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	39K	20K	0	0	0	0	0	0
Total Liabilities	1.39M	1.5M	2.44M	2.09M	793K	926K	3.91M	3.88M	1.41M	13.8M
Total Debt+	0	0	0	0	0	25K	450K	483K	383K	968K
Net Debt	-15.35M	-38.8M	-7.4M	-8.7M	-6.61M	-8.34M	-48.62M	-52.88M	-42.06M	-60.61M
Debt / Equity	-	-	-	-	-	0.00x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-830.57x	-1085.11x	-	-	-60.03x
Total Equity+	14.74M	38.07M	22.19M	10.28M	6.03M	7.61M	46.52M	51.04M	41.67M	382.22M
Equity Growth %	-0.05%	1.58%	-0.42%	-0.54%	-0.41%	0.26%	5.11%	0.1%	-0.18%	8.17%
Book Value per Share	1087.17	1307.48	528.71	212.76	94.08	69.12	9.88	3.67	2.89	22.77
Total Shareholders' Equity	14.74M	38.07M	22.19M	10.28M	6.03M	7.61M	46.52M	51.04M	41.67M	382.22M
Common Stock	21K	9K	9K	12K	14K	2K	10K	14K	14K	37K
Retained Earnings	-84.62M	-96.07M	-112.51M	-131M	-138.93M	-144.42M	-154.15M	-173.48M	-183.4M	-83.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-19K	-2K	0	0	0	0	0	-41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Cash from Operations+	-9.41M	-10.53M	-14.99M	-17.47M	-8.24M	-4.8M	-7.72M	-18.76M	-10.91M	-57.84M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.78%	-0.12%	-0.42%	-0.17%	0.53%	0.42%	-0.61%	-1.43%	0.42%	-4.3%
Net Income	-9.69M	-11.45M	-16.44M	-18.49M	-7.93M	-5.48M	-9.74M	-19.32M	-9.93M	-83.72M
Depreciation & Amortization	12K	19K	24K	27K	22K	89K	93K	91K	114K	27K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	714K	788K	1.03M	906K	275K	151K	43K	497K	561K	14.27M
Working Capital Changes	-443K	104K	400K	85K	-608K	441K	1.88M	-28K	-1.66M	11.59M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	-583K	-392K	188K	1.1M	-411K	-783K	3.46M
Cash from Investing+	-19K	-11K	-16.41M	12.93M	3.05M	-4K	-19K	-43K	-2K	-330.13M
Capital Expenditures	-19K	-11K	-12K	-3K	-4K	-4K	-19K	-43K	-2K	-189K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	8.02M	33.99M	0	5.85M	3.1M	6.56M	48.45M	23.09M	0	449.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-179K	-193K	0	-256K	-311K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.43M	-10.54M	-15M	-17.48M	-8.25M	-4.8M	-7.74M	-18.8M	-10.91M	-58.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.77%	-0.12%	-0.42%	-0.17%	0.53%	0.42%	-0.61%	-1.43%	0.42%	-4.32%
FCF per Share	-695.11	-362.16	-357.31	-361.85	-128.64	-43.64	-1.64	-1.35	-0.76	-3.46
FCF Conversion (FCF/Net Income)	0.97x	0.92x	0.91x	0.94x	1.04x	0.88x	0.79x	0.97x	1.10x	0.69x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
Return on Equity (ROE)	-63.91%	-43.34%	-54.57%	-113.89%	-97.3%	-80.37%	-35.98%	-39.61%	-21.41%	-39.5%
Return on Invested Capital (ROIC)	-	-	-177.22%	-171.5%	-1221.36%	-	-	-	-	-41.15%
Debt / Equity	-	-	-	-	-	0.00x	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-	-	-	-	-	-830.57x	-1085.11x	-	-	-60.03x
FCF Conversion	0.97x	0.92x	0.91x	0.94x	1.04x	0.88x	0.79x	0.97x	1.10x	0.69x

Frequently Asked Questions

Growth & Financials

Oruka Therapeutics, Inc. (ORKA) grew revenue by 0.0% over the past year. Growth has been modest.

Oruka Therapeutics, Inc. (ORKA) reported a net loss of $109.2M for fiscal year 2024.

Dividend & Returns

Oruka Therapeutics, Inc. (ORKA) has a return on equity (ROE) of -39.5%. Negative ROE indicates the company is unprofitable.

Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $84.6M in fiscal year 2024, likely due to heavy capital investments.